Advertisement

Targeted and Immune Therapy for Periocular and Orbital Malignancies

  • Oded Sagiv
  • Bashar Jaber
  • Bita EsmaeliEmail author
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

The use of targeted therapy and immune checkpoint inhibitors have significantly contributed to the treatment of patients with locally advanced, unresectable metastatic periocular cancers. Sonic Hedgehog inhibitors are used to treat locally advanced or metastatic periocular basal cell carcinoma and have been found to enable a less-extensive definitive surgery. Epidermal growth factor receptor antagonists have been used to treat patients with locally advanced periocular squamous cell carcinoma with a significant reduction in tumor size and improvement in quality of life. BRAF inhibitors, with or without concurrent MEK inhibitors, have been used to treat patients with cutaneous melanoma metastatic to the orbit. Immune checkpoint inhibitors have been used to treat patients with orbital metastasis from cutaneous melanoma and patients with eyelid and conjunctival metastatic melanoma. The authors of the chapter have also observed preliminary positive response in locally advanced recurrent periocular squamous cell carcinoma treated with immune checkpoint inhibitors. These promising results for treatment of both locally advanced and metastatic periocular tumors should encourage ophthalmologists and oculoplastic surgeons to implement these treatments in appropriate cases as described in this chapter.

Keywords

Sonic hedgehog inhibitors Periocular basal cell carcinoma Epidermal growth factor receptor antagonist periocular squamous cell carcinoma BRAF inhibitors MEK inhibitors Metastatic melanoma Conjunctival melanoma Immune checkpoint inhibitors 

References

  1. 1.
    US-FDA. FDA labeling information—ERIVEDGE. FDA website. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf.
  2. 2.
    Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9.CrossRefGoogle Scholar
  4. 4.
    Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729–36.PubMedCrossRefGoogle Scholar
  5. 5.
    Jacobsen AA, Aldahan AS, Hughes OB, et al. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152(7):816–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Ozgur OK, Yin V, Chou E, et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220–227.e222.PubMedCrossRefGoogle Scholar
  7. 7.
    Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1720–31.PubMedCrossRefGoogle Scholar
  8. 8.
    Yin VT, Esmaeli B. Targeting the hedgehog pathway for locally advanced and metastatic basal cell carcinoma. Curr Pharm Des. 2017;23(4):655–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Demirci H, Worden F, Nelson CC, et al. Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area. Ophthal Plast Reconstr Surg. 2015;31(6):463–6.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Wong KY, Fife K, Lear JT, et al. Vismodegib for locally advanced periocular and orbital basal cell carcinoma: a review of 15 consecutive cases. Plast Reconstr Surg Glob Open. 2017;5(7):e1424.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    US-FDA. FDA labeling information—ODOMZO. FDA website. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266s000lbl.pdf.
  12. 12.
    Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–5.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    US_Department_of_Health_Human_Services. Common terminology criteria for adverse events (CTCAE) version 4.03, 2010. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2016.Google Scholar
  16. 16.
    Ally MS, Tang JY, Lindgren J, et al. Effect of calcium channel blockade on vismodegib-induced muscle cramps. JAMA Dermatol. 2015;151(10):1132–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Moreira J, Tobias A, O’Brien MP, Agulnik M. Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies. Drugs. 2017;77(8):843–57.PubMedCrossRefGoogle Scholar
  18. 18.
    Shepler TR, Prieto VG, Diba R, et al. Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthal Plast Reconstr Surg. 2006;22(2):113–5.PubMedCrossRefGoogle Scholar
  19. 19.
    US-FDA. FDA labeling information—ERBITUX. FDA website. 2004. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125084s168lbl.pdf.
  20. 20.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Acevedo-Henao CM, Valette G, Miglierini P, et al. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity. Cancer Radiother. 2012;16(7):601–3.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Knoedler M, Gauler TC, Gruenwald V, et al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology. 2013;84(5):284–9.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13(23):7086–92.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Herchenhorn D, Dias FL, Viegas CM, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2010;78(3):696–702.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Hainsworth JD, Spigel DR, Greco FA, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J (Sudbury, Mass). 2011;17(5):267–72.CrossRefGoogle Scholar
  27. 27.
    Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31(11):1415–21.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77–85.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    El-Sawy T, Sabichi AL, Myers JN, et al. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012;130(12):1608–11.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012;119(9):1798–802.PubMedCrossRefGoogle Scholar
  31. 31.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Cosgarea I, Ritter C, Becker JC, et al. Update on the clinical use of kinase inhibitors in melanoma. J Dtsch Dermatol Ges. 2017;15(9):887–93.PubMedGoogle Scholar
  33. 33.
    US-FDA. FDA labeling information—ZELBORAF. FDA website. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdf.
  34. 34.
    US-FDA. FDA labeling information—TAFLINAR. FDA website. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf.
  35. 35.
    US-FDA. FDA labeling information—MEKINIST. FDA website. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf.
  36. 36.
    McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–72.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.PubMedCrossRefGoogle Scholar
  39. 39.
    Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.PubMedCrossRefGoogle Scholar
  41. 41.
    Larsen AC, Dahl C, Dahmcke CM, et al. BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions. Acta Ophthalmol. 2016;94(5):463–70.PubMedCrossRefGoogle Scholar
  42. 42.
    Griewank KG, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013;19(12):3143–52.PubMedCrossRefGoogle Scholar
  43. 43.
    Dagi Glass LR, Lawrence DP, Jakobiec FA, Freitag SK. Conjunctival melanoma responsive to combined systemic BRAF/MEK inhibitors. Ophthal Plast Reconstr Surg. 2017;33(5):e114–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Liu M, Yang X, Liu J, et al. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(19):32258–69.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Peng L, Wang Y, Hong Y, et al. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 2017;8(47):83280–91.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Yin VT, Wiraszka TA, Tetzlaff M, et al. Cutaneous eyelid neoplasms as a toxicity of vemurafenib therapy. Ophthal Plast Reconstr Surg. 2015;31(4):e112–5.PubMedCrossRefGoogle Scholar
  47. 47.
    US-FDA. FDA labeling information—OPDIVO. FDA website. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s024lbl.pdf.
  48. 48.
    US-FDA. FDA labeling information—KEYTRUDA. FDA website. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s015lbl.pdf.
  49. 49.
    US-FDA. FDA labeling information—YERVOY. FDA website. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s074lbl.pdf.
  50. 50.
    US-FDA. FDA labeling information—BAVENCIO. FDA website. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf.
  51. 51.
    Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Barone A, Hazarika M, Theoret MR, et al. FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin Cancer Res. 2017;23(19):5661–5.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Beaver JA, Theoret MR, Mushti S, et al. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin Cancer Res. 2017;23(14):3479–83.PubMedCrossRefGoogle Scholar
  55. 55.
    Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Hazarika M, Chuk MK, Theoret MR, et al. U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res. 2017;23(14):3484–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–43.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Ford J, Thuro BA, Thakar S, et al. Immune checkpoint inhibitors for treatment of metastatic melanoma of the orbit and ocular adnexa. Ophthal Plast Reconstr Surg. 2017;33(4):e82–5.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–29.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic SurgeryThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.St John Eye Hospital GroupJerusalemIsrael

Personalised recommendations